Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Compared to Big Oil, Big Pharma's looking pretty good
May 9, 2006
By: Tim Wright
Editor-in-Chief, Contract Pharma
Politics makes fools of us all. From pushing Part D to blocking Plan B, from trying to free drug reimportation to restricting sales of OTC decongestants, our politicians have demonstrated an uncanny ability to pick the most wrong path, expertly avoiding gridlock only long enough to promote policies that will cause the most confusion and inconvenience at the highest price. This past month, they’ve managed to avoid inflicting themselves on the Pharma industry by grandstanding against the oil industry. It’s a seasonal occurrence: “driving season” coincides with increased gasoline prices and Congress calls for an investigation. At no point does Congress consider its own complicity in this issue (if you think it’s a coincidence that we’re forcing ethanol blends in our gas and putting high tariffs on foreign sources of ethanol, then you probably don’t know anything about Iowa’s electoral history in presidential elections), and never looks beyond the numbers at the gas station. As columnist and economics professor Brad De Long recently put it, “Democrats are (because of the environmentalist wing of the party) generally in favor of higher gasoline taxes and higher gasoline prices-except when gasoline prices are high. Republicans are in favor of letting oil markets ‘work’-except when gasoline prices are high.” So now we get the idiocy of a proposed “windfall tax,” because “oil companies are making too much money.” We’ve had the requisite photo-ops of senators and representatives standing in front of a gas station (while their aides keep the SUVs idling nearby), and soon we’ll have the requisite investigation to determine that the laws of supply and demand are working just fine. Meanwhile, the gas station down the street from my home has been open for only one of the past seven days, because those ethanol regulations have created a shortage in properly blended gasoline. I bring this up because it contrasts with the recent mini-revolt at Pfizer. At the company’s annual shareholders meeting in April, two proxy advising companies called for the removal of board members as a response to the retirement package that awaits chairman and chief executive officer Hank McKinnell in 2008. In one of those unfathomable (to the rest of us) lottery moments, Mr. McKinnell will get to pick between a $6.5 million annual pension or a lump sum of $83 million. Since Pfizer’s stock hasn’t done well in recent years, some shareholders don’t think he should be so rewarded. For some reason, the AFL-CIO decided to protest outside the meeting, to make themselves feel relevant. Of course, Mr. McKinnell didn’t get to this point by letting a PowerBall machine in the local 7-11 randomly pick numbers; he shepherded Pfizer to the point at which its revenues are more than 50% higher than that of its closest competitor. Now, those of you who have been reading this column for a while (or my Top Companies reports every summer) know that I’m not a fan of Pfizer’s “biggest is best” strategy. To quickly recap: I don’t believe R&D is scalable (after a certain point), and I don’t believe that a large buy-in strategy is workable in the long-term. But, you know what? That’s why I don’t invest in Pfizer’s stock! I’m not trained in high finance, but I look at the acquisitions, the pipeline, the generic attrition, and I figure that’s not a stock to put my money in. And, you know what else? Other people disagree with me! They may find value in other aspects of Pfizer, or maybe they’re just more optimistic about the company’s ability to develop and market new products. Maybe they’re smarter than I am. Maybe some of them are dumber, and just invest in whatever the “biggest” company is in any field. That’s how the market works. People buy shares, or they sell them (well, they occasionally short them, which gets Biovail really mad). At the end of the day, the stock price is what it is. If the shareholders have a gripe with management, they can take it up at shareholders meetings. Obviously, a single shareholder isn’t going to make any impact; it’s the large-block holders (think state pension groups) that can start to cause trouble. But it was the shareholders that raised the protest against Mr. McKinnell’s pension package, not Congress.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !